Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 19/05/2008

    "Fast-track" route to a PhD degree

    The Chemical Biology graduate school at Constance University was officially opened on 7th May 2008. It was created as part of Germanys excellence initiative and has been training doctoral students since the beginning of April 2008.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/fast-track-route-to-a-phd-degree
  • Press release - 07/12/2021

    New approach developed to predict response of immunotherapies in lung cancer

    At Tübingen University Hospital, a preclinical study led by Dr. Clemens Hinterleitner and Prof. Dr. Lars Zender, Medical Director of Medical Oncology and Pneumology, led to extremely promising results. The research group was able to develop a new methodology that makes it possible to better predict the likelihood of success of immunotherapies for lung cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-developed-predict-response-immunotherapies-lung-cancer
  • Press release - 14/03/2012 16661_de.jpg

    How a natural antibiotic found in sweat affects microorganisms

    The skin creates a barrier between the body and its environment. Natural antibiotics that can kill potential pathogens such as bacteria or fungi represent an additional level of protection by the immune system. Dermcidin one such antibiotic produced in human sweat glands is active against a number of microorganisms on the skin. A team of scientists from the University Hospital Tübingen and the Max Planck Institute for Developmental Biology were…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-a-natural-antibiotic-found-in-sweat-affects-microorganisms
  • Press release - 03/03/2020

    CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force

    Daniel Menichella, CEO of biopharmaceutical company CureVac, was today invited to the White House to discuss strategies and opportunities for the rapid development and production of a coronavirus vaccine with U.S. President Donald Trump, Vice President Mike Pence, members of the White House Coronavirus Task Force and high-ranking representatives of pharmaceutical and biotech companies working on the outbreak’s response.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-CEO-Daniel-Menichella-Discusses-Coronavirus-Vaccine-Development-with-U-S-President-Donald-Trump-and-Members-of-Coronavir
  • Press release - 15/07/2021

    Mechanism for differentiation of specific immune cell types discovered

    Under certain conditions, our immune system can efficiently fight off infectious diseases and cancer. T cells, especially the gamma delta T cell type, play an important role in this. The issue is that this cell type is extremely infrequent in the human body. Researchers at the University Hospital Tübingen, the University of Heidelberg and the European Molecular Biology Laboratory (EMBL) have now succeeded in finding the cause for the formation of…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mechanism-differentiation-specific-immune-cell-types-discovered
  • Press release - 01/02/2021

    Targeting a rapid market breakthrough for new vaccine production method

    In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-rapid-market-breakthrough-new-vaccine-production-method
  • Press release - 07/08/2009 Immunofluorescence image of the enteric nervous system in a mouse. The red fluorescing neurons form a complex network in the intestinal wall.

    Hirschsprung’s disease: research into the biological and clinical principles of stem cell therapy

    Hirschsprung’s disease is a congenital disease of the intestinal nervous system, which can lead to life-threatening bowel disorders. A new research project, which is being coordinated by the Centre for Regenerative Biology and Medicine (ZRM) in Tübingen, is paving the way for a novel cell therapy. The project is being carried out in co-operation with the NMI in Reutlingen and is being funded by a 1.1-million-euro BMBF-grant.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hirschsprung-s-disease-research-into-the-biological-and-clinical-principles-of-stem-cell-therapy
  • Press release - 30/03/2009

    Stem Cells: Deathly Awakening by Interferon

    Interferon-alpha, a messenger substance of the immune system, awakens dormant hematopoietic stem cells in the bone marrow to become active, thus making them vulnerable for the effect of many drugs. This finding was published in Nature by researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) jointly with colleagues from Lausanne. The researchers suppose that this might also be a way to stimulate tumor stem…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/stem-cells-deathly-awakening-by-interferon
  • SolidCAR-T project - 15/03/2022 Drawing illustrating the individual steps inside a mini-factory, starting with the collection of T lymphocytes, the preparation, processing and post-processing of the CAR T cells and ending with the treatment of the patient.

    Modular ‘mini-factories’ for decentralised production of CAR T cells

    Novel CAR T-cell therapies have proved to be promising therapeutic options for the treatment of acute leukaemias and lymphomas. Researchers from the Fraunhofer IPA in Stuttgart, the University Hospital Tübingen and the NMI in Reutlingen have joined forces in the SolidCAR-T project that aims to generate CAR T cells to combat solid tumours and produce these cells directly on site in the clinic using automated 'mini-factories'.

    https://www.gesundheitsindustrie-bw.de/en/article/news/modular-mini-factories-decentralised-production-car-t-cells
  • Vaccine development - 02/11/2015 Valerie_Herrmann.jpg

    A new vaccine could prevent influenza epidemics

    Influenza pandemics are dangerous and can claim many lives. Children and the elderly in particular run a high risk of developing influenza-related complications, because their immune system is often weakened by the virus. In Germany, annual vaccination against seasonal influenza has therefore been recommended for these target groups for quite a few years now. However, producing vaccines is costly and time-consuming. Researchers at the University…

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-new-vaccine-could-prevent-influenza-epidemics
  • Article - 20/09/2016 Prof. Dr. Anita Marchfelder, spokesperson and coordinator of the DFG research group FOR1680.

    CRISPR-Cas has more surprises in store

    Since 2012, a DFG-funded research group called FOR1680 has been studying CRISPR-Cas, an immune system that unicellular bacteria and arachaea use to protect themselves against attacks from viruses and plasmids. Prof. Dr. Anita Marchfelder, a molecular biologist at Ulm University and coordinator of the FOR1680 research group, and many other researchers were surprised to find that prokaryotes incorporate the genetic material of enemies as a kind of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/crispr-cas-has-more-surprises-in-store
  • Article - 18/02/2013 18791_de.jpg

    AIDS researchers from Ulm to shed light on the success of the HIV-1 M group

    Frank Kirchhoff AIDS researcher at the University of Ulm has come up with a plausible explanation for the pandemic spread of the human immunodeficiency virus 1 HIV-1 M group and its ability to adapt to the human immune system. In a recent study with colleagues from Germany and abroad Kirchhoff used molecular biology methods to investigate the group and compare it with the relatively rare HIV-1 N group. Kirchhoff hopes that the molecular…

    https://www.gesundheitsindustrie-bw.de/en/article/news/aids-researchers-from-ulm-to-shed-light-on-the-success-of-the-hiv-1-m-group
  • Article - 16/01/2012 Dr. Alexander Titz, chemist at the University of Konstanz

    Alexander Titz: molecular design to combat antibiotic-resistant bacteria

    Pseudomonas aeruginosa has become an important cause of infection, and is often picked up in hospitals, especially by patients with weakened immune systems. It can cause respiratory and urinary tract infections, as well as lead to infections on implants and wounds. P. aeruginosa lives in a gel-like matrix, a so-called biofilm that is highly resistant to antibiotics, making it very difficult to eradicate. Dr. Alexander Titz and his team at the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/alexander-titz-molecular-design-to-combat-antibiotic-resistant-bacteria
  • Press release - 08/10/2012 10529_de.jpg

    Affimed raises € 15.5 million in a Series D financing round

    Affimed Therapeutics AG the therapeutic TandAb antibody company announced the successful closing of a Series D financing round of 15.5 million on 8 October 2012. The proceeds from this transaction will be used to fund the clinical development of Affimeds therapeutic pipeline that consists of two TandAb products AFM11 and AFM13. Both candidates have unique properties as shown in preclinical studies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-raises-15-5-million-in-a-series-d-financing-round
  • Press release - 13/11/2012 18685_de.jpg

    immatics’ renal cancer vaccine IMA901 completes phase 3 patient recruitment

    immatics biotechnologies GmbH announced that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma RCC. The first interim overall survival results are expected during the first half of 2014.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-renal-cancer-vaccine-ima901-completes-phase-3-patient-recruitment
  • Article - 12/11/2012 18619_de.jpg

    Autoimmune diseases – when the body sheds its skin

    Most people believe that snakes and insects are the only animals able to shed their skin. However autoimmune diseases of the largest human organ i.e. the skin can have a similar effect by creating blisters scars peeling and wet wounds. Dr. Cassian Sitaru from the University of Freiburg Medical Centre specifically focuses on blistering autoimmune dermatoses. Using disease models in Petri dishes and laboratory mice Sitaru and his team hope to find…

    https://www.gesundheitsindustrie-bw.de/en/article/news/autoimmune-diseases-when-the-body-sheds-its-skin
  • Article - 19/09/2019 Die Biologin im Labor mit Algen in Glasflaschen

    Magnetised algae as microrobots for medical and environmental purposes

    Algae, for most of us, is something that lives in water courses that we occasionally find unpleasant. However, that is to do them a wrong. These extremely versatile and frugal organisms might in future prove to be extremely important. Scientists at the University of Stuttgart are investigating how algae can be used as microrobots in biomedicine and environmental remediation.

    https://www.gesundheitsindustrie-bw.de/en/article/news/magnetisierte-algen-als-mikroroboter-fuer-medizin-und-umwelt
  • Dossier - 10/03/2014 20939_de.jpg

    Cancer therapy and cancer diagnostics

    Thanks to improved diagnostics and therapy, today’s cancer patients can live considerably longer than patients several years ago. Nevertheless, some cancers, especially the strongly metastatic ones, are difficult to treat. Therapies targeting immune cells or cancer stem cells could potentially improve the current situation. The early detection and classification of tumours is crucial for the successful treatment of the disease, and molecular…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-therapy-and-cancer-diagnostics
  • Press release - 15/10/2020

    Common Vulnerabilities of Coronaviruses

    International study in which Freiburg scientists are participating maps molecular targets for possible therapy for MERS, SARS-CoV1, and SARS-CoV2.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/common-vulnerabilities-coronaviruses
  • Press release - 12/03/2009 Haematopoietic stem cells can be best studied in living organisms.

    New strategy for the investigation of haematopoietic stem cells

    With the newly developed mouse model irradiation is no longer required. While the mutation in the growth factor receptor Kit KitWWv weakens the recipients stem cell compartment and makes room for the incoming donor cells the other two mutations are known to prevent rejection of donor haematopoietic stem cells by the recipients immune system. Thus these mice appear to accept all blood stem cells regardless of the mouse strain origin of the…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-strategy-for-the-investigation-of-haematopoietic-stem-cells
  • Article - 22/02/2016 Close-up of a blood-sucking Anopheles mosquito.

    Generating malaria parasite gene deletion mutants

    The fight against malaria is one of the targets of goal 3 of the Sustainable Development Goals (SDGs) (ensuring healthy lives and promote well-being for all at all ages). The research carried out by Prof. Dr. Frischknecht and Mirko Singer from the Centre for Infectious Diseases at Heidelberg University Hospital is one of several steps towards eradicating malaria.

    https://www.gesundheitsindustrie-bw.de/en/article/news/generating-malaria-parasite-gene-deletion-mutants
  • Article - 20/11/2011 Lactic acid bacteria under the microscope. The photo shows black rods moving around on pink tissue.<br /> <br />

    Can probiotic lactic acid bacteria protect the intestines against pathogens?

    Nutrition scientists from the Max Rubner-Institut MRI in Karlsruhe are investigating how human pathogens and probiotic bacterial strains interact with each other in the human gastrointestinal tract. Are probiotic bacteria in yoghurt or in pickled vegetables for example able to reduce the health risk posed by pathogenic bacteria?

    https://www.gesundheitsindustrie-bw.de/en/article/news/can-probiotic-lactic-acid-bacteria-protect-the-intestines-against-pathogens
  • Article - 14/02/2011 The photo shows a model of a protein.

    A molecule that enables local virus defence

    Dr. Markus Mordstein has spent the last four years as a doctoral student at the University of Freiburg investigating the previously relatively unknown interferon lambda. He has been able to show that this molecule has similar protective functions to type I interferons and he has also found that it is far more selective in terms of the site where it exerts its effect.

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-molecule-that-enables-local-virus-defence
  • Article - 04/02/2020 Teaser_Meeresschnecke_biosyn.jpg

    Medicine from the blue blood of marine mollusks

    A “living pharmacy” crawls on the ocean floor off the coastline that stretches from Southern California to Mexico: biosyn Arzneimittel GmbH, a pharmaceutical company based in the city of Fellbach in southern Germany, produces a drug to treat bladder cancer, using the haemolymph, a vertebrate fluid equivalent to blood, of Megathura crenulata, commonly known as a giant keyhole limpet.

    https://www.gesundheitsindustrie-bw.de/en/article/news/medicine-from-blue-blood-marine-snails
  • Press release - 23/05/2011 14384_de.jpg

    Interactive exhibition on health opened on Mainau Island

    Can neurons grow together again? Is the immune system able to combat cancer? Can a chip help blind people regain their sight? As part of the “Science in Dialogue” (Wissenschaft im Dialog) initiative, the “Lindau Nobel Laureate Meetings” foundation has organised an exhibition on health-related topics that will be open to visitors until 4th September 2011. BIOPRO Baden-Württemberg is in pavilion 11 presenting three exciting research topics from…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/interactive-exhibition-on-health-opened-on-mainau-island

Page 6 / 11

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 11
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search